NDAINJECTIONINJECTABLE
Approved
Dec 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Clinical Trials (2)
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Started Feb 2009
0Nephrogenic Systemic FibrosisRenal Insufficiency
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients
Started May 2002
100 enrolled
Pathological Processes
Company
Guerbet
France - Villepinte
External Resources